In addition, strategies that further increased production of ROS by blocking alternate antioxidant pathways (i.e., TXNR) or compromising DNA repair (PARP inhibition; BRCA2 mutation) exacerbated this DNA damage leading to synergistic PCa cell killing and inhibition of PCa tumor growth. The gene discussed is PARP1; the disease is neoplasm.